Early Breast Cancer Clinical Trials in Nanjing, Jiangsu
3 recruitingNanjing, Jiangsu, China
Showing 1–3 of 3 trials
Recruiting
Phase 3
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Early Breast Cancer
Novartis Pharmaceuticals1,400 enrolled217 locationsNCT05827081
Recruiting
Phase 2
Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast Cancer
HR+/HER2- Early Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University100 enrolled3 locationsNCT07616427
Recruiting
Phase 2
Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer
Early Breast Cancer
The First Affiliated Hospital with Nanjing Medical University1,163 enrolled1 locationNCT06341894